Taipei Veterans General Hospital is a national first-class medical center and a teaching hospital that provides tertiary patient care, undergraduate medical education programs and residency programs in Taiwan. It was founded in 1958 and administered by the Veterans Affairs Council.

During the past decade, Taipei Veterans General Hospital conducted 528 clinical trials. In the 10-year time frame, 528 clinical trials started and 148 clinical trials were completed, i.e. on average, 28% percent of trials that started reached the finish line to date. In the past 5 years, 262 clinical trials started and 101 clinical trials were completed. i.e. 38.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Taipei Veterans General Hospital" #1 sponsor was "Taipei Veterans General Hospital, Taiwan" with 137 trials, followed by "Pfizer" with 43 trials sponsored, "Hoffmann-La Roche" with 27 trials sponsored, "Boehringer Ingelheim" with 22 trials sponsored and "Eli Lilly and Company" with 22 trials sponsored. Other sponsors include 448 different institutions and companies that sponsored additional 219 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Taipei Veterans General Hospital" #1 collaborator was "Taipei Veterans General Hospital, Taiwan" with 38 trials as a collaborator, "National Taiwan University Hospital" with 21 trials as a collaborator, "Chang Gung Memorial Hospital" with 18 trials as a collaborator, "National Cheng-Kung University Hospital" with 18 trials as a collaborator and "China Medical University Hospital" with 16 trials as a collaborator. Other collaborators include 276 different institutions and companies that were collaborators in the rest 165 trials.

According to Clinical.Site data, the most researched conditions in "Taipei Veterans General Hospital" are "Hepatocellular Carcinoma" (20 trials), "Gastric Cancer" (14 trials), "Breast Cancer" (13 trials), "Non-small Cell Lung Cancer" (13 trials) and "Non-Small Cell Lung Cancer" (12 trials). Many other conditions were trialed in "Taipei Veterans General Hospital" in a lesser frequency.

Most popular intervention types in "Taipei Veterans General Hospital" are "Drug" (521 trials), "Device" (69 trials), "Other" (64 trials), "Biological" (56 trials) and "Procedure" (27 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (117 trials), "Cisplatin" (23 trials), "Gemcitabine" (18 trials), "Pembrolizumab" (18 trials) and "Carboplatin" (16 trials). Other intervention names were less common.

The vast majority of trials in "Taipei Veterans General Hospital" are 637 trials for "All" genders, 48 trials for "Female" genders and 17 trials for "Male" genders.

Currently, there are 269 active trials in "Taipei Veterans General Hospital". 5 are not yet recruiting, 147 are recruiting, 114 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 272 completed trials in Taipei Veterans General Hospital, 1 suspended trials, and 58 terminated clinical trials to date.

Out of the total trials that were conducted in Taipei Veterans General Hospital, 96 "Phase 1" clinical trials were conducted, 174 "Phase 2" clinical trials and 270 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 44 trials, and there were also 98 trials that are defined as “Not Applicable".